STLN

Starling Oncology Inc.

STLN | NASDAQ

Price Alert Chart Builder DCF Calculator

$6.53

-$0.12 (-1.80%)

At close: Oct 30, 2026, 3:59 PM ET

$6.41

-$0.12 (-1.84%)

Pre-market: Nov 2, 2026, 4:48 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-1.80%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

32.5

+8.5 pts

Fundamentals Weak

Market Sentiment Neutral

Moat None

Sector Rank #727/1028 (Top 71%)

Full Analysis

Key Statistics

Market Data

Market Cap $652.39M

1D Range

6.35 6.69

52W Range

4.99 7.05

Valuation (TTM)

PE -21.77

PB -26.19

EV/EBITDA -32.75

Valuation (NTM)

Forward PE N/A

Forward PEG 0.30

Price Target $9.00

Cash Flow

FCF Yield -0.5%

SBC Adj. FCF Yield -1.3%

SBC Impact -155.1%

Margins

Gross Margin 15.7%

Operating Margin -4.4%

FCF Margin -0.6%

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y N/A | N/A

FCF 3Y | 5Y N/A | N/A

Returns

ROA -20.4%

ROE 209.8%

ROIC -28.8%

Financial Health

Net Debt

$38.77M

Current Ratio 1.36

Interest Coverage -3.42

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-b...

Sector Healthcare

Industry Medical - Care Facilities

Employees 641

IPO Date Aug 4, 2026

Website www.starlingoncology.com

Fiscal Year n/a

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$9.00

Upside

+37.83%

Buy (3)

Hold (0)

Sell (0)

Analyst Details ➞